The warning comes from Radformation, which has just added a prior authorization QA capability to QuickCode, its automated billing QA platform. But the problem is bigger than any product: it grows out of the distance between the plan described in the authorization and the treatment that clinical reality forced the team to deliver.<\/p>\n Radiation therapy carries the highest prior authorization burden of any specialty in medicine. The survey ASTRO ran in late 2024 quantifies the damage: 92% of radiation oncologists<\/strong> reported adverse patient impact tied to prior authorization denials. Roughly one third reported patients who abandoned or forwent treatment because of a denial. And 30% of providers cited concrete outcomes directly attributable to those denials \u2014 emergency department visits, hospitalizations and even death.<\/p>\n The administrative load keeps climbing too: 51% of respondents<\/strong> said more than half of their 2024 cases required prior authorization, a metric that has risen year over year since at least 2019. Understandably, attention concentrates on front-end denials, the ones that delay treatment initiation, push a case toward a less-than-optimal technique or kill it outright. Back-end denials slip by precisely because the patient has already been treated.<\/p>\n The triggers are almost always administrative, which is exactly what makes them galling:<\/p>\n None of this is exotic. A patient who gets sick, travels or interrupts treatment pushes the course out by days or weeks; if the final fractions land outside the authorized window, the claim is denied. A single clerical slip in a code produces the same result. Since one course of radiation therapy can represent thousands to tens of thousands of dollars in reimbursement, every lost claim hurts \u2014 especially with margins under the pressure that drove ASTRO’s push for the ROCR Act to keep community clinics open<\/a>.<\/p>\n A post-treatment denial is not just a line in a financial report. It cascades into unrecoverable department revenue, the administrative burden of appeals, unexpected financial responsibility landing on the patient, less staff time spent on care, heightened compliance and audit scrutiny, and eroded satisfaction scores and departmental reputation. Most denial dashboards capture only the first item.<\/p>\n That cost stacks on top of what patients already carry. The literature on financial toxicity in radiation oncology<\/a> is clear that an unexpected bill during or after cancer treatment has clinical consequences, not merely accounting ones: patients skip follow-up, ration medication or stop showing up.<\/p>\n Traditional prevention is manual: someone reviews the approved authorization, compares it with the delivered treatment and releases the claim. That works at low volume with a full team. With rising volumes, labor shortages and administrative burnout, the review simply does not happen before submission. And like any repetitive task performed by tired people, it is highly error-prone \u2014 human error is widely considered one of the leading causes of denials in radiation oncology and in medical billing generally.<\/p>\n Radformation’s answer is to automate the reconciliation: the tool ties authorization data directly to the patient’s clinical reality as recorded in the system and flags discrepancies before the claim is finalized. Checks span procedure code and quantity, plan change and technique validation, timing and milestone requirements, dates of service and schedule, and diagnosis code alignment. The platform now also carries internal “cheat sheets”, letting staff document payer-specific requirements and reminders inside the system itself \u2014 a small feature that fixes a real problem, namely institutional knowledge living in one person’s head.<\/p>\n The practical takeaway does not depend on buying anything. It is to make pre-billing reconciliation a formal step in the workflow rather than a favor someone does when there is time. Three checks resolve most cases: the technique actually delivered matches the technique authorized; the number of fractions and fields fits inside what was approved; and the last fraction fell within the authorization’s validity period. When treatment changes mid-course, the amended authorization request has to leave the same day the clinical decision is made, not at month-end close.<\/p>\n It also pays to keep a payer-by-payer record of quirks \u2014 which ones require a new authorization for a boost, which ones count fractions rather than weeks, which ones enforce a hard end date. That knowledge is what separates a department that appeals denials from one that never generates them. Coding accuracy belongs in the same conversation, and it moves every year, as the 2026 radiology CPT code changes<\/a> illustrated.<\/p>\n Expect more friction, not less. With the share of cases subject to authorization climbing since 2019 and reimbursement pressure intensifying \u2014 see the proposed 2027 Medicare fee schedule<\/a> \u2014 radiation oncology’s administrative bill is likely to grow faster than its revenue. Billing QA automation is unglamorous, which is exactly why it sits last in the investment queue. That priority deserves revisiting: in a department treating a few hundred patients a year, preventing half a dozen denied claims pays for the software. The obvious limitation is that no tool fixes a badly negotiated contract or a payer rule that changes without notice; what it does is stop a department from losing money for a reason that was already documented in its own system.<\/p>\n![\"Two](\"https:\/\/rtmedical.com.br\/wp-content\/uploads\/2026\/07\/glosas-autorizacao-previa-radioterapia.jpg\")
ASTRO’s numbers show the size of the hole<\/h2>\n
What triggers a post-treatment denial<\/h2>\n
\n
The invisible cost goes beyond lost revenue<\/h2>\n
Why manual reconciliation does not scale<\/h2>\n
How to operationalize it in any department<\/h2>\n
Outlook<\/h2>\n